Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Positive Comparator, Randomized, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients with Mild to Moderate Dementia of the Alzheimer's Type (AD).

Trial Profile

A Double-Blind, Positive Comparator, Randomized, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of AZD3480 (TC-1734-226) as Monotherapy in Patients with Mild to Moderate Dementia of the Alzheimer's Type (AD).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 12 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ispronicline (Primary) ; Donepezil
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Targacept
  • Most Recent Events

    • 15 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Jul 2014 Primary endpoint 'change from Baseline to week 52 in ADAS-Cog-11 and the Clinician Interview- Based Impression of Change Plus Caregiver Input (CIBIC-(+))' has not been met according to the Targacept media release.
    • 14 Jul 2014 Primary endpoint 'Change from Baseline to Week 52 in the co-primary endpoints ADAS-Cog-11 and the ADCS-ADL' has not been met (for European regulatory purposes) according to the Targacept media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top